HugoFernandezMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Professor, Oncologic Sciences, USF-Morsani

Dr. Fernandez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
603 N Flamingo Rd
Ste 151
Hollywood, FL 33028
Phone+1 954-265-4325

Fax+1 954-443-4747

University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1991 - 1994
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1987 - 1991
University of Florida College of MedicineClass of 1987

PubMed

149 citations
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
Laura Barreyro, Britta Will, Boris Bartholdy, Li Zhou, Tihomira I. Todorova
Blood. 2012-08-09
125 citations
PHF6 mutations in adult acute myeloid leukemia.
P. Van Vlierberghe, Jawaharlal M. Patel, Omar Abdel-Wahab, Camille Lobry, Cyrus V. Hedvat
Leukemia. 2011-01-01
2043 citations
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E. Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S. Ward, Jay P. Patel
Cancer Cell. 2010-12-14

Abstracts/Posters

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hepatic Veno-Occlusive Disease Following Sirolimus-Based Immune Suppression
Hugo Fernandez, MD, Nature, Orlando, FL, 12/9/2019
Join now to see all

New Memorial Cancer Institute Puts World-Class Care Under One RoofOctober 19th, 2023
Health | Memorial Healthcare Unveils Its New, High-Tech Cancer Center in West BrowardNovember 24th, 2023